NY-BCW
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced the addition of top public affairs and technology experts to its U.S. team: Terry Neal has joined the firm as Executive Vice President, Managing Director, Public Affairs and James Cook has joined as Executive Vice President, Managing Director, New York Technology. Neal is based in Washington, D.C. and Cook is based in New York.
“Terry and James represent the high caliber of talent that BCW attracts, which makes us such a powerful partner to our clients,” said Chris Foster, President, North America, BCW. “Both Terry and James are world-class counselors with deep experience working with Fortune 100 clients and developing integrated communications solutions that make an impact on clients’ bottom lines. I am confident that Terry’s background in journalism and his expertise in advising on policy and regulatory matters, and James’s global perspective and track record in building business, will be of enormous value to our clients.”
Neal has more than two decades of experience in media, advocacy and strategic communications, managing multi-platform campaigns for clients spanning the automotive, consultancy, energy, financial and technology industries. He also is a veteran crisis counselor, having advised government agencies and sovereign nations on their communications needs. Before joining BCW, he ran his own consultancy, Neal Communication Strategies, LLC, and served with The Podesta Group, Fannie Mae, CGI Federal, Light Squared and Hill + Knowlton Strategies. Neal began his career in the media, as a national political reporter, columnist and editor at The Washington Post, Miami Herald and Fort Lauderdale Sun-Sentinel. As a newspaper reporter, Neal had more than 2,000 published bylines and more than 200 television appearances across CNN, MSNBC, NBC and PBS.
Cook has more than 20 years of experience working both in agencies and in-house, creating and implementing integrated communications strategies for consumer, corporate and technology companies ranging from early stage start-ups to large multinationals. He has extensive expertise in devising, planning and implementing global, North America, Asia, UK and pan-European communications campaigns, including management and coordination of a network of global / regional agencies. Cook joined BCW from Edelman where he led Revere NY, Edelman’s in-house technology boutique, where he doubled revenue in one year. Cook also led the Artificial Intelligence Center of Excellence in Edelman’s New York office. Before that he spent eight years with Edelman in Beijing and Singapore, running their respective technology practices. Earlier in his career he held senior roles with MSL in Toronto and Weber Shandwick in Beijing, Toronto and London driving double-digit revenue growth in each role.
About BCW
BCW is one of the world’s largest full-service global communications agencies. Founded by the merger of Burson-Marsteller and Cohn & Wolfe, BCW delivers digitally and data-driven creative content and integrated communications programs grounded in earned media and scaled across all channels for clients in the B2B, consumer, corporate, crisis management, CSR, healthcare, public affairs and technology sectors. BCW is a part of WPP (NYSE: WPP), the world's leader in communications services. For more information, visit www.bcw-global.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181008005786/en/
Contact:
Media Contact: BCW Catherine Sullivan, 212-798-9501 Catherine.Sullivan@bm.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
